BiotechTube

Pembrolizumab + EDP1503

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma (Skin)

Conditions

Melanoma (Skin), Melanoma

Trial Timeline

Oct 2, 2018 → Jul 31, 2025

NCT ID
NCT03595683

About Pembrolizumab + EDP1503

Pembrolizumab + EDP1503 is a phase 2 stage product being developed by Merck for Melanoma (Skin). The current trial status is terminated. This product is registered under clinical trial identifier NCT03595683. Target conditions include Melanoma (Skin), Melanoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03595683Phase 2Terminated

Competing Products

20 competing products in Melanoma (Skin)

See all competitors
ProductCompanyStageHype Score
Binimetinib Oral TabletBiotrialPhase 1
25
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
77
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
25
FYB206 + KeytrudaFormycon AGPhase 1
25
PLX3397Daiichi SankyoPre-clinical
23
PLX3397 + PembrolizumabDaiichi SankyoPhase 1/2
41
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
DS-8273a + NivolumabDaiichi SankyoPhase 1
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
33
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
YM155Astellas PharmaPhase 2
52
YM155 + DocetaxelAstellas PharmaPhase 2
52
Denileukin diftitoxEisaiPhase 2
52
E7080EisaiPhase 1
33
lenvatinib + pembrolizumabEisaiPhase 2
52
MORAb-004 (monoclonal antibody)EisaiPhase 2
52
Pembrolizumab + LenvatinibEisaiPhase 2
52
Lenvatinib + Lenvatinib + DacarbazineEisaiPhase 1/2
41

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85